• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gastric reactive capillary hemangioma caused by tislelizumab.

作者信息

Long Xin, Zhang Huipeng, Yin Tengfei, Zhang Jing, Yu Yanbo, Gao Yanjing

机构信息

Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, China.

出版信息

Endoscopy. 2025 Dec;57(S 01):E941-E942. doi: 10.1055/a-2657-0108. Epub 2025 Aug 20.

DOI:10.1055/a-2657-0108
PMID:40834897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12367400/
Abstract
摘要

相似文献

1
Gastric reactive capillary hemangioma caused by tislelizumab.替雷利珠单抗引起的胃反应性毛细血管瘤。
Endoscopy. 2025 Dec;57(S 01):E941-E942. doi: 10.1055/a-2657-0108. Epub 2025 Aug 20.
2
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.11 种治疗方案对晚期野生型鳞状非小细胞肺癌中国患者的有效性和成本效益分析：序贯模型。
Front Public Health. 2023 Feb 24;11:1051484. doi: 10.3389/fpubh.2023.1051484. eCollection 2023.
3
Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report.接受替雷利珠单抗联合化疗的转移性胃癌患者完全缓解：一例报告
Front Oncol. 2023 May 10;13:1147636. doi: 10.3389/fonc.2023.1147636. eCollection 2023.
4
Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.替雷利珠单抗联合化疗对比单纯化疗用于局部晚期胃癌新辅助治疗的安全性和有效性：连续患者队列的真实世界经验。
Front Immunol. 2023 May 4;14:1122121. doi: 10.3389/fimmu.2023.1122121. eCollection 2023.
5
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.替雷利珠单抗对比卡瑞利珠单抗二线治疗局部晚期或转移性食管鳞癌的成本效果分析。
BMC Health Serv Res. 2024 May 29;24(1):676. doi: 10.1186/s12913-024-11142-5.
6
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.替雷利珠单抗联合化疗与安慰剂联合化疗作为晚期胃或胃食管交界腺癌一线治疗的疗效比较：RATIONALE-305研究中的患者报告结局
Curr Med Res Opin. 2025 Jun;41(6):1007-1016. doi: 10.1080/03007995.2025.2501588. Epub 2025 Jun 18.
7
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.一线替雷利珠单抗联合化疗治疗程序性死亡配体1表达≥1%的晚期胃癌：RATIONALE-305回顾性分析
Adv Ther. 2025 May;42(5):2248-2268. doi: 10.1007/s12325-025-03133-7. Epub 2025 Mar 13.
8
Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report.卡瑞利珠单抗（SHR-1210）导致牙龈反应性毛细血管瘤：一例报告。
World J Clin Cases. 2020 Feb 6;8(3):624-629. doi: 10.12998/wjcc.v8.i3.624.
9
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.替雷利珠单抗联合化疗对比安慰剂联合化疗一线治疗晚期胃或胃食管结合部腺癌：RATIONALE-305 随机、双盲、III 期临床试验。
BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876.
10
Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer.病例报告：S-1/奥沙利铂方案联合曲妥珠单抗和替雷利珠单抗治疗局部晚期胃癌患者后的病理完全缓解
Front Oncol. 2024 Sep 5;14:1425572. doi: 10.3389/fonc.2024.1425572. eCollection 2024.

本文引用的文献

1
An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.口腔中出现的类似牙龈瘤的卡瑞利珠单抗相关反应性皮肤毛细血管内皮增生（RCCEP）：一例报告。
Oral Oncol. 2023 May;140:106369. doi: 10.1016/j.oraloncology.2023.106369. Epub 2023 Mar 28.
2
Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review.口服反应性毛细血管血管瘤由 SHR-1210 诱发治疗非小细胞肺癌：病例报告及文献复习。
BMC Oral Health. 2021 Nov 2;21(1):559. doi: 10.1186/s12903-021-01901-9.
3
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.